A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

NCT01625260 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to low enrollment.

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

BIOLOGICAL: ALT-801
DRUG: Gemcitabine

Sponsor

Altor BioScience

Collaborators

[object Object]